DR. RUBIN’S ANXIETY PILL MADE OF CANNABIS TO HIT THE MARKET NEXT WEEK

Thousand Oaks, CA, Dec. 07, 2020 (GLOBE NEWSWIRE) — CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK: CBDG) developer of a unique line of premium CBD based oral health products, today announced that it had completed the research and development of a groundbreaking new CBD based dental anxiety formulation that will be available next week for purchase on CBDUAL’S website and participating dental offices.

Research shows that cannabidiol (CBD) can help ameliorate severe medical symptoms from multiple sclerosis, cancer, Parkinson’s, Alzheimer’s, anxiety, and depression.

CBD products have been of interest in treating both socially and physically-based anxiety disorders. The FDA approved the use of cannabidiol in treating epilepsy. A recent clinical trial has shown that CBD can effectively reduce anxiety.

The Permanente Journal published a study reporting that 79% of participants experienced a reduction in anxiety after ingesting cannabinoids. Hence, these preliminary results on CBD’s positive effects have caused mental health advocates to consider CBDs for their anti-anxiety properties.

Even though the way CBD works to treat anxiety isn’t fully understood, it hasn’t stopped millions of people in need of symptom relief from using CBDs. It is reported in a 2019 Gallup Poll that 14% of Americans use CBD.

Research indicates that the prevalence of dental anxiety in the US is about 10-20 percent of patients visiting dental offices. Regression analysis revealed several factors associated with dental anxiety, the most significant of which are: unfavorable attitude towards and fear that dentists will cause pain. Dentists are aware of these and other factors when assessing dental anxiety in their patient populations. They are looking for alternative ways to reduce dental anxiety during visits.

The American Dental Association (ADA) names fear and dental anxiety as one of the reasons people avoid proper dental care. Also, 1 in 5 adults experience anxiety due to the health condition of their mouth and teeth, 22% of patients are afraid of dentists. This is a severe problem since the health of one’s mouth is paramount to the general; overall, the physical and mental health of each individual.

There are currently over 200,000 practicing dentists in the United States. Each dentist is seeing approximately 3500 patient/visits per year. The Company conservatively estimates the potential market size for its CBD dental anxiety products could to be $70,000,000 per year.

“As a leader in the field of CBD based dental and oral hygiene formulations, our primary goal is to research and manufacture CBD products made from plant-derived, organically-grown US hemp from trusted growers,” says Dr. Greg Rubin, CEO of CBDUAL Biotechnology Corp.

For more information and to preorder, please email: info@cbdual.com

ANNUAL REPORT

THC Farmaceuticals Inc (OTC PINK: CBDG)   has published its fiscal year ending September 30, 2020, annual report. Under new SEC rules, OTC Pink companies may now publish their financial statements on their websites in lieu of publication on the OTCMarkets.com website and therefore, until further notice, CBDG will publish its financial statements here: http://cbdg.com/investor-relations/financials/

About CBDual Biotechnology Corp.

THC Farmaceuticals, Inc.: (OTC: CBDG) through its subsidiary, CBDual Biotechnology Corp., is a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The Company’s facility is located in Southern California. We provide easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual Biotechnology Corp is a privately held, US Based Biotechnology company with proprietary technology for enhanced oral delivery of bioactive cannabinoids . This technology promotes overall oral health due to the higher effectiveness of the delivery methodology. The Company was founded in 2016 and is headquartered in California, with its R&D in the US and Israel.

On November 26, 2018, the Company took its first steps to become the world’s first public Company to enter the magic mushroom space, subsequently forming its subsidiary, Medical Mushrooms  Ltd.

Recently the Company has begun research on psilocybin for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin formulations. We are well-positioned to begin clinical trials involving psilocybin since we have already cleared a path for cannabis-related clinical trials. The purpose of this division is to engage in advanced research of the growing niche of pharmaceutical-grade medicinal mushrooms, including psychedelics. The Company has registered the following domain names:

http://www.psycomagic.info

http://www.magicpharmaceuticals.com

http://www.psycomagic.com

For additional information, visit the Company’s website: http://cbdual.com/ and http://cbdg.com/

Follow us on Twitter @THCFarma and @CBDualBiotech.

Forward-Looking Statements:

This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

SOURCE NEWSWIRE